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S228 Poster Session IBackground:Cord blood transplantation (CBT) is potentially cura-
tive for patients with hematologic diseases, yet many patients are in-
eligible for conventional myeloablative conditioning due to prior
therapies, age, and co-morbidities. Treosulfan is an alklyating agent
with myeloablative, immunosuppressive, and antineoplastic activity,
with predictable pharmacokinetics and a favorable toxicity profile.
However, there is limited evidence using Treosulfan in the cord
blood transplant setting.
Methods:We investigated the efficacy of Treosulfan-based condi-
tioning prior to CBT in patients unable to tolerate myeloablative
total body irradiation (TBI) but at high risk for relapse, to demon-
strate that Treosulfan/Fludarabine/TBI was sufficient to promote
CB engraftment. Patients received Treosulfan 14 gm/m2 IV days
-6 to -4, Fludarabine 30 mg/m2 IV days -6 to -2, and 200 cGy
TBI day -1. Graft-versus-host disease (GVHD) prophylaxis was
Cyclosporine and MMF. Cumulative incidence (CI) rates were
used to estimate engraftment and relapse, treating death as a com-
peting risk. Kaplan-Meier analysis was used to estimate overall
survival (OS).
Results: 15 patients aged 4-63 years (median 48), with AML (n5 7),
ALL (n5 4), MDS (n5 2), CML (n5 1), and CMML (n5 1) have
been treated, with a median follow-up of 181 days (range 31-415). 9
patients had disease (n5 3) or minimal residual disease (MRD) (n5
6) at time of transplant. 13 patients received double CBT; 7 patients
received 4/6-matched units, 7 received 5/6-matched, and 1 received
6/6-matched units. The CI of neutrophil engraftment was 85.7%
(95% CI: 53.9-96.2), occurring at a median of 22.5 days (IQR
17.5-29). Only 1 patient had primary graft failure. The CI of relapse
was 26.7% (95% CI: 5.9-54); 2 patients developed MRD at days 28
and 80, and one patient relapsed at day 180. Grade II-IV acute
GVHD (aGVHD) developed in 11/15 patients (overall aGVHD
scores 2-3); there were no cases of grade IV aGVHD. There have
been 5 deaths on protocol: 2 from multi-system organ failure at
days 34 and 40, and 3 deaths from relapse.
Conclusions: Treosulfan provides adequate conditioning to pro-
mote engraftment after CBT in a single center analysis of 15 patients,
and provides an alternate preparative regimen for patients unable to
tolerate TBI-based therapy. Conditioning with Treosulfan was
well-tolerated, and can be used with CBT to extend the donor
pool to patients without conventional donors who are ineligible for
other myeloablative regimens.204
ALLOGENEIC STEM CELL TRANSPLANTATION FROM DONORS OTHER
THAN HLA-MATCHED SIBLINGS IN PEDIATRIC PATIENTS: FAMILY BANK
Hamidieh, A.A., Ostadali, M., Jalili, M., Behfar, M., Basirpanah, S.,
Houseini, A., Bakhti, O., Ghavamzadeh, A. TehranUniversity of Medical
Sciences, Tehran, Islamic Republic of Iran
Objective: Allogeneic haematopoietic stem cell transplantation
(HSCT) has been used to treat a variety of diseases including
malignant and nonmalignant diseases. Best choice of a donor is
a sibling matched donor. However, more than 70% of patients
who need a transplant will have not such donors. For the
patients, donors can be found in the extended family of the patient
or in registries of unrelated donors or cord blood banks. The
purpose of this study is to investigate HSCT from other related
donors.
Methods: During January 2008 to September 2010, we searched in
specified members of a family to detected related donor for 210 pa-
tients who lack a sibling donor and their parents’ marriage was con-
sanguineous marriage. High resolution typing for class I and II
alleles was completed for recipient/donor pairs.
Results:The result of search in the extended family was successful in
43 out of 210 of patients (20.4%) who didn’t have HLAmatched sib-
ling donors. Median age was 5 (range: 1-15 year) that 62.8% was
male. 43 patients with major thalassemia (n 5 11), acute leukemia
(n5 10), fanconi anemia (n5 8), severe aplastic anemia (n5 4), pri-
mary immunodeficiency (n 5 4), histocytic disorder (n 5 2), hurlersyndrome (n 5 2) and osteopetrosis (n 5 2) were selected. The
stem cell source was bone marrow in 30 and peripheral blood in
13 patients. The donors were parents (n5 29), grandfather or grand-
mother (n 5 5) and uncle or aunt (n 5 9). All the 43 patients en-
grafted with neutrophils (. 500/micro L) at a median of 14 days.
15 out of 43 patients who engrafted (37.2%) were complicated by
Acute GVHD. Transplantation related mortality occurred in 2
patients (4.6%).
Conclusion: We have a potentially available donor registry (family
bank) in some countries that consanguineous marriage is not forbid-
den, such as Iran and eastern Mediterranean. While many countries
have very limited numbers of donor registries and cord blood banks,
this type of ‘‘Family Bank’’ can be very helpful and important donor
source. Therefore, all of transplant unit especially in these countries
have to evaluate each single patient before searching in unrelated do-
nor registry and cord blood banks in case of patient who are without
matched sibling donor.205
SUCCESSFUL ENGRAFTMENT AND REDUCED EARLY MORTALITY IN
UNRELATED DONOR (UD) CORD BLOOD (CB) STEM CELL TRANSPLANTA-
TION (SCT) USING A PREPARATIVE REGIMEN OF THIOTEPA, FLUDARA-
BINE, MELPHALAN AND RABBIT ANTI-THYMOCYTE GLOBULIN (TFM/
R-ATG) IN OLDER ADULTS WITH A SINGLE UNMANIPULATED CB UNIT
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Background: UD-CBSCT in adult patients is associated with
a high incidence of graft failure (10-20%) and increased mortality.
Optimal preparative regimen for CBSCT is currently unknown.
Myeloablative regimens in older adults result in high mortality
while nonmyeloablative regimens have increased graft failure. We
report universal engraftment and reduced early mortality in older
adults who underwent single unit CBSCT with TFM/r-atg as pre-
parative regimen.
Materials and Methods: Retrospective analysis was performed on
all patients who underwent single unit UD-CBSCT at the Umass
medical center over a one year period using TFM/r-atg as prepara-
tive regimen.
Results: Nine patients underwent single unit UD-CBSCT from
April 2009 to March 2010. Diagnosis included MDS/AML (6),
CLL (2) and ALL (1). 6/9 patients had persistent disease. The me-
dian age was 62 years (range 44 to 69) and median weight was 98.1
kg (range 52.6 to 109.3). There were 5 males and 4 females. Pre-
parative regimen consisted of thiotepa 10 mg/kg day -7, fludarabine
30 mg/m2 from day -6 to -2, melphalan 110 to 140 mg/m2 day -1
and r-atg 3 mg/kg given over 2 days (day -4, -3). Graft versus host
disease (gvhd) prophylaxis consisted of mycophenolate mofetil (day
-1 to 56) and tacrolimus (level 5-15 ng/ml) starting day -1. HLA
matching in the direction of rejection was 6/6 in 1; 5/6 in 3 and
4/6 in 5 cases. HLA matching in the direction of gvhd was 6/6
in 1; 5/6 in 2 and 4/6 in 6 cases. The median total nucleated cell
(TNC) dose based on pre-cryopreserved sample was 3.11 (range
2.26 to 5.21)  107/kg. Patients were infused a median of 2.6 
107 TNC /kg (range 1.3 to 3.4) and 0.78  105 CD34 cells/kg
(range 0.016 to 1.56)). All 9 patients successfully engrafted. The
median time to neutrophil engraftment was 20 range (13 -38)
days and platelet engraftment was 44 range (34 to 73) days. All pa-
tients achieved full donor chimerism at engraftment. 100 day and
one year survival are 89% (1/9) and 55% (5/9) respectively. Causes
of death include toxicity 2; gvhd 1; relapse 1; and JC virus associ-
ated PML in one patient. Four patients are currently alive and in
complete remission 12, 15, 16 and 18 months post transplant. All
four patients surviving patients were gvhd free and off all systemic
immunosuppressants at one year post transplant.
Poster Session I S229Conclusion: TFM/r-ATG preparative regimen results in universal
engraftment with a low early mortality and a reasonable long term
survival in older adults with a single unit UD-CBSCT.IMMUNE RECONSTITUTION
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TIMESENSITIVEPARAMETERSOF IMMUNERECONSTITUTIONMEASURED
BETWEEN DAY 100 AND 1 YEAR PREDICT SURVIVAL AFTER UNRELATED
CORDBLOODTRANSPLANT(UCBT):THEDYNAMICIMPACTOFDENDRITIC
CELLS,TREGS,ANDTHYMICRECOVERY
Szabolcs, P.1,2, Mendizabal, A.M.3, Wilfret, D.A.1, Reese, M.1,
Vinesette, R.1, Page, K.M.1, Parikh, S.H.1, Kurtzberg, J.1 1Duke
University, Durham, NC; 2Duke University, Durham, NC; 3The
EMMES Corporation, Rockville, MD
Objective: Reconstitution of dendritic cells (DC) and lymphocytes
is critical for protective immunity, however, the tempo of their re-
covery is variable and their impact at specific time points on UCBT
outcome is not defined. This study aims to analyze the impact of
cellular immune reconstitution within the first year.
Methods: Between 07/05 and 12/07, 93 children with full donor
chimerism following myeloablative conditioning were longitudi-
nally assessed at Day (D) 100, 180, 270 and 365 for reconstitution
of DC and T cell subsets, B and NK cells by 4 color FACS to
determine thresholds associated with overall survival (OS).
Parameters were dichotomized at the median (M) of each time
point and hazard ratios estimated by Cox proportional hazards
analysis.
Results: Patients were transplanted for non-malignant (N 5 63)
and malignant diseases (N 5 30). M age was 2.1 years, 58%
male, 36% were 4/6, 42% were 5/6 and 23% were 6/6 HLA
matched. The M infused TNC and CD341 cell dose was
7.3x107/kg and 1.9x105/kg, respectively. 22 patients died within 2
years: OS at 2-years 76%. At D100, lower percentage and abso-
lute numbers of regulatory T cells (CD251/CD62L1/
CD41Tregs) was associated with death (p 5 0.04 and p 5 0.02).
A higher fraction of ‘‘activated’’ HLA-DR expressing CD81 T
cells predicted death at D100 with marginal significance at 180
and 270 while absolute numbers significant at D270. At D180, a pe-
riod when thymic function may resume, a rise in ‘recent thymic
emigrants’ was associated with survival (RTE, CD45RA1/
CD62L1 T cells), p 5 0.01 and p 5 0.04. Higher levels of ‘plas-
macytoid’ CD1231 DC were consistently associated with better
OS after D100 (p \ 0.05). Major lymphocyte subsets, B, NK,
CD31, CD41 T cells were NOT associated with superior OS ex-
cept at D180 with all lymphocytes combined, exceeding an ALC of
. 1180/ul (p 5 0.04). Table 1 depicts the Hazard Ratios for the
above immune parameters with cut-offs at the median values.
Conclusions: Our data demonstrate that different immune cells
will have unique kinetics and dynamics of recovery that confer
shifting power in predicting outcome at different time points
within the first year. Nevertheless, by the second half of the first
year, superior pDC and RTE recovery along with a reduced activa-
tion state (%HLA-DR) are independently associated with better
OS. These results should facilitate the development of risk models
for the early identification of those at highest risk of death and who
may benefit from novel immunotherapies.
Table 1. Cellular Factors of Immune Reconstitution Associ-
ated with Death After UCBT
TimeParameterPoint
(Day)Cut -Off
Level Hazard Ratio P- ValueAbsolute Lymphocyte
Count /ul180 # 1180 1.0000180 > 1180 0.3175 (0.1052-0.958) 0.0417CD45RA+ /62L+ (RTE)
(% of CD3+)180 # 7 1.0000180 > 7 0.2403 (0.079-0.7308) 0.012CD45RA+ / CD62L+
(RTE) (% CD4+)180 # 4 1.0000(Continued )Table 1. (Continued )ParameterTime
Point
(Day)Cut -Off
Level Hazard Ratio P- Value180 > 4 0.343 (0.1222-0.9628) 0.0422CD25+ /CD62L+ (T-Reg)
(% of CD4+)100 # 22.5 1.0000100 >22.5 0.3337 (0.1186-0.9385) 0.0375Absolute Number of CD25+
/CD62L+/CD4+ T-Reg/ul100 # 23 1.0000100 > 23 0.252 (0.0828-0.767) 0.0152HLA-DR+ (Activated)
(% of CD8+)100 # 46.5 1.0000100 > 46.5 4.3873 (1.4253-13.5047) 0.0099180 # 29.0 1.0000180 > 29.0 2.5483 (0.9553-6.7973) 0.0617270 # 15 1.0000270 > 15 3.215 (0.8527-12.1217) 0.0846Absolute Number of HLA-
DR+ /CD8+ T cells/ul270 # 11.9 1.0000270 > 11.9 5.0176 (1.0837-23.2329) 0.0391Absolute Number of CD123+
(pDC) (Cells / ul)180 # 7.5 1.0000180 > 7.5 0.3394 (0.1207-0.9545) 0.0405270 # 6.7 1.0000270 # 6.7 0.2063 (0.0446-0.9552) 0.0435365 # 8.2 1.0000365 > 8.2 0.0862 (0.011-0.6758) 0.0197Hazard Ratio’s and ( p-values) at each time point207
RAPID CHIMERISM – SWITCH OF LYMPHOCYTES AND PHENOTYPIC
CONVERSION OF NA€ıVE T CELLS EARLY AFTER CORD BLOOD TRANS-
PLANTATION
Yamamoto, H.1, Matsuno, N.1,2, Watanabe, N.2, Narita, M.1,
Nishida, A.1, Ishiwata, K.1, Nakano, N.1, Tsuji, M.1, Tsuchihashi, R.1,
Asano-Mori, Y.1, Uchida, N.1, Izutsu, K.1, Wake, A.1, Nakauchi, H.2,
Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan; 2The Institute of
Medical Science, the University of Tokyo, Tokyo, Japan
Background:Tounderstand the pathogenesis of allogeneic immune
reaction early after cord blood transplantation (CBT), we analyzed
the kinetics of donor-chimerism and T-cell phenotype during early
period after CBT.
Methods: Analysis of chimerism was performed on CD3, CD4,
CD8, andCD56 fractions of peripheral blood byHLA-Flowmethod
on 1, 2, 3, 4, and 8 weeks after CBT. T-cell phenotype was analyzed
by flow-cytometry on 2, 4, and 8 weeks after CBT in engrafted
patients.
Results: Forty-eight patients were enrolled in this study. The pa-
tients had a median age of 57.5 years (range, 19-71 years). All except
for two patients received fludarabine-based conditioning. GVHD
prophylaxis was mainly composed of tacrolimus and mycophenolate
mofetil (n 5 35). Forty-one patients achieved neutrophil engraft-
ment at a median of 20 days (range, 13-44 days). Using HLA-Flow
method for the chimerism analysis (n 5 32), the engrafted patients
(n 5 28) showed rapid switch to donor-type dominant chimerism;
the median percentages of donor-derived CD41 T-cells, CD81 T-
cells and NK cells at one week were 89.8% (range, 19.1-100%),
91.7% (range, 9.3-100%) and 95.3% (range, 23.5-100%), respec-
tively, and all the patients reached complete donor chimerism by 3
weeks. In phenotypical analysis (n 5 42), the proportions of na€ıve
phenotype (CD45RA1 CCR71) in CD41 and CD81 T-cells at 2
weeks decreased rapidly to a median of 55% (range, 10-90%) and
20% (range, 1-88%), respectively.
Conclusions: We observed rapid chimerism-switch of lympho-
cytes along with early T-cell differentiation from na€ıve to mem-
ory phenotype after CBT. These findings may explain the
mechanisms behind severe immune-mediated complications
following CBT.
